Science Takeda Unveils Promising Phase 3 Results for Psoriasis Drug Zasocitinib An announcement on December 18 revealed that Takeda has achieved positive topline results from two pivotal Phase 3 studies involving zasocitinib (TAK-279), a treatment... Editorial10 January, 2026